CN103989835A - Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof - Google Patents
Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof Download PDFInfo
- Publication number
- CN103989835A CN103989835A CN201410193441.8A CN201410193441A CN103989835A CN 103989835 A CN103989835 A CN 103989835A CN 201410193441 A CN201410193441 A CN 201410193441A CN 103989835 A CN103989835 A CN 103989835A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- extract
- compositions
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for reducing blood sugar, decreasing blood fat and protecting liver and a preparation method and an application thereof. The composition comprises the following components, by weight, 480-720 parts of a balsam pear extract, 400-600 parts of a cinnamon extract, 400-600 parts of root of kudzu vine, 480-720 parts of cassia seed, 480-720 parts of wolfberry, 240-360 parts of a grape skin extract, 320-480 parts of a ginseng extract, 20-30 parts of chromium-enriched yeast, 12-18 parts of xanthophylls, 320-480 parts of magnesium oxide, 16-24 parts of zinc oxide, 12.8-19.2 parts of vitamin B1, 12.8-19.2 parts of vitamin B2, 6.4-9.6 parts of vitamin B6, 0.28-0.42 part of folic acid, and 0.0064-0.0096 part of vitamin B12. The product provided by the invention is safe and effective, has a good curative effect of reducing blood sugar and blood fat, and has a good effect of treating liver damage.
Description
Technical field
The present invention relates to a kind of compositions, particularly relate to a kind of Chinese medicine composition with blood sugar lowering, blood fat reducing, liver protection effect and its preparation method and application.
Background technology
Hyperlipidemia refers to a kind of disease disease that cholesterol, triglyceride, phospholipid and the not esterified lipid compositions such as fat acid in blood plasma increases.Hyperlipidemia is the risk factor of systemic atherosclerosis, there are some researches prove, and hyperlipemia, blood lipid level declines 1%, and the mortality rate of cardiovascular and cerebrovascular disease can decline 2%.Therefore, reduce the important and effective means that blood lipid level is prevention and treatment cardiovascular and cerebrovascular disease.
Hyperlipemia is the frequently-occurring disease of middle-aged and elderly people, and with advancing age and growth in the living standard, prevalence is also increase trend, and research finds that hypercholesterolemia is relevant with atherosclerosis and coronary heart disease.Most of blood lipid-lowering medicines all have significant untoward reaction, and often have knock-on tendency.Therefore the non-nutrient that dietary factor particularly exists in food has wide prospect to the prevention of hyperlipidemia and treatment.
When exceeding the level of regulation, blood glucose value will form hyperglycemia.Our times has diabetics 1.3 hundred million people, and every year with 1% speed increase.A lot of diabetes patients are with hyperlipemia, so people call sister's disease diabetes and hyperlipemia conventionally, and think that hyperlipidemia is the secondary disease of diabetes.About 40% diabetic has disorders of lipid metabolism according to statistics.
Chemical liver injury, its chemical toxicant is of a great variety, general susceptible in crowd.Chemical toxicant destroys hepatocyte by oxidation reaction, changes structure and the function of cell, causes hepatic injury, larger to human health damage.
The medicine of existing treatment hyperglycemia, hyperlipidemia generally be take Western medicine as main, and only part Chinese medicine does not often have the effect of hepatoprotective, nourishing the liver concurrently.Therefore, from green plants, exploitation has the medicine that control chemical liver injury can reduce blood glucose, blood fat simultaneously and has important economic worth and clinical meaning.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition that blood sugar lowering, effect for reducing blood fat also have liver protection effect concurrently that not only has.
For reaching above-mentioned purpose, a kind of blood sugar lowering of the present invention, blood fat reducing, the compositions of liver protection effect, the component that comprises following weight portion: Fructus Momordicae charantiae extract 480-720 part, Cortex Cinnamomi extract 400-600 part, Radix Puerariae 400-600 part, Semen Cassiae 480-720 part, Fructus Lycii 480-720 part, Pericarpium Vitis viniferae extract 240-360 part, Radix Ginseng extract 320-480 part, Rich chromium yeast 20-30 part, phylloxanthin 12-18 part, magnesium oxide 320-480 part, zinc oxide 16-24 part, VB11 2.8-19.2 part, vitamin B2 12.8-19.2 part, vitamin B6 6.4-9.6 part, folic acid 0.28-0.42 part, vitamin B12 0.0064-0.0096 part.
Further, compositions of the present invention, preferably includes the component of following weight portion: 600 parts of Fructus Momordicae charantiae extracts, 500 parts of Cortex Cinnamomi extracts, 500 parts of Radix Puerariaes, 600 parts of Semen Cassiaes, 600 parts of Fructus Lycii, 300 parts of Pericarpium Vitis viniferae extract, 400 parts of Radix Ginseng extracts, 25 parts of Rich chromium yeasts, 15 parts of phylloxanthins, 400 parts of magnesium oxide, 20 parts of zinc oxide, 6 parts of VB11s, 16 parts of vitamin Bies, 8 parts of vitamin Bies, 0.35 part, folic acid, 0.008 part of vitamin B12.
In the present composition, described Fructus Momordicae charantiae extract, Cortex Cinnamomi extract, Pericarpium Vitis viniferae extract, Radix Ginseng extract can obtain by purchase, as can be purchased from Xuancheng plant Trade Co., Ltd..
Compositions of the present invention, it can be the various conventional oral preparation of Chinese traditional medicinal that contains or do not contain pharmaceutic adjuvant, as powder, capsule, tablet or granule.
The invention still further relates to the method for the above-mentioned powder of preparation, capsule, tablet, take the raw material of above-mentioned weight proportion, pack and obtain powder after mix homogeneously, every bag contains present composition 2g, takes one bag every day, one day twice.
By above-mentioned raw materials by described weight proportion mix homogeneously after fill capsule obtain capsule, or after raw material mix homogeneously, add silicon dioxide or magnesium stearate fill capsule to obtain capsule, every capsules contains present composition 0.5g, each serving with 4, and twice of every day.
By after above-mentioned raw materials mix homogeneously, add microcrystalline Cellulose, carboxymethyl starch sodium, and use PVP K30 pelletize, then add lubricant, tabletting obtains tablet or granulator granulation obtains granule, pack.Every contains present composition 0.5g, and every bag of granule contains present composition 2g.Tablet is each serving with 4, and every day twice, granule is each serving with one bag, one day twice.
Further, preferably add the amount of silicon dioxide or magnesium stearate to account for the 0.8-1.2% of gross weight.The weight ratio of preferred described microcrystalline Cellulose and compositions is 1:4, and the weight ratio of described carboxymethyl starch sodium and compositions is 1:20, and the weight ratio of described PVP K30 and compositions is 1:33.
The application of the present composition, can be used for health food or medicine that preparation has blood sugar lowering, blood fat reducing, liver protection effect.
The invention difference from existing technology is, the present invention has the Chinese medicine composition of blood sugar lowering, blood fat reducing, liver protection effect, take Fructus Momordicae charantiae extract, Cortex Cinnamomi extract, Radix Puerariae, Semen Cassiae, Fructus Lycii, Pericarpium Vitis viniferae extract and Radix Ginseng extract as main component, be aided with the compositions such as Rich chromium yeast, phylloxanthin, zinc oxide, vitamin, folic acid, through simple hybrid process, make, preparation method is easy, has retained well Effective Component of Chinese Medicine.By lot of experiments, prove, product safety of the present invention is effective, not only blood sugar lowering, blood fat is had to good curative effect, and has good therapeutical effect for hepatic injury.
The specific embodiment
Below in conjunction with embodiment and test data, to the present invention is above-mentioned, be described in more detail with other technical characterictic and advantage.
Embodiment 1
Accurately weigh the raw material of following weight: Fructus Momordicae charantiae extract 480g, Cortex Cinnamomi extract 600g, Radix Puerariae 600g, Semen Cassiae 480g, Fructus Lycii 480g, Pericarpium Vitis viniferae extract 360g, Radix Ginseng extract 480g, Rich chromium yeast 30g, phylloxanthin 18g, magnesium oxide 320g, zinc oxide 16g, VB11 9.2g, vitamin B2 12.8g, 9.6 parts of g of vitamin B6, folic acid 0.42g, vitamin B12 0.0096g.
To after above-mentioned raw materials mix homogeneously, pack and obtain powder.
Fill capsule after above-mentioned raw materials mix homogeneously is obtained to capsule, or after raw material mix homogeneously, add silicon dioxide or magnesium stearate fill capsule to obtain capsule, wherein the addition of silicon dioxide or magnesium stearate accounts for 0.8% of gross weight.
By after above-mentioned raw materials mix homogeneously, add microcrystalline Cellulose, carboxymethyl starch sodium, and use PVP K30 pelletize, then add lubricant, tabletting obtains tablet or granulator granulation obtains granule.
Embodiment 2
Accurately weigh the raw material of following weight: Fructus Momordicae charantiae extract 720g, Cortex Cinnamomi extract 400g, Radix Puerariae 400g, Semen Cassiae 720g, Fructus Lycii 720g, Pericarpium Vitis viniferae extract 240g, Radix Ginseng extract 320g, Rich chromium yeast 20g, phylloxanthin 12g, magnesium oxide 480g, zinc oxide 24g, VB11 2.8g, vitamin B2 19.2g, vitamin B6 6.4g, folic acid 0.28g, vitamin B12 0.0064g.
To after above-mentioned raw materials mix homogeneously, pack and obtain powder.
Fill capsule after above-mentioned raw materials mix homogeneously is obtained to capsule, or after raw material mix homogeneously, add silicon dioxide or magnesium stearate fill capsule to obtain capsule, wherein the addition of silicon dioxide or magnesium stearate accounts for 1.2% of gross weight.。
By after above-mentioned raw materials mix homogeneously, add microcrystalline Cellulose, carboxymethyl starch sodium, and use PVP K30 pelletize, then add lubricant, tabletting obtains tablet or granulator granulation obtains granule.
Embodiment 3
Accurately weigh the raw material of following weight: Fructus Momordicae charantiae extract 600g, Cortex Cinnamomi extract 500g, Radix Puerariae 500g, Semen Cassiae 600g, Fructus Lycii 600g, Pericarpium Vitis viniferae extract 300g, Radix Ginseng extract 400g, Rich chromium yeast 25g, phylloxanthin 15g, magnesium oxide 400g, zinc oxide 20g, VB11 6g, vitamin B2 16g, vitamin B6 8g, folic acid 0.35g, vitamin B12 0.008g.
To after above-mentioned raw materials mix homogeneously, pack and obtain powder.
Fill capsule after above-mentioned raw materials mix homogeneously is obtained to capsule, or after raw material mix homogeneously, add silicon dioxide or magnesium stearate fill capsule to obtain capsule, wherein the addition of silicon dioxide or magnesium stearate accounts for 1.0% of gross weight.。
By after above-mentioned raw materials mix homogeneously, add microcrystalline Cellulose 1000g, carboxymethyl starch sodium 200g, and with the pelletize of 121.2g PVP K30, then add lubricant, tabletting obtains tablet or granulator granulation obtains granule.
The hypoglycemic curative effect of test example 1 present composition
1. materials and methods
1.1 sample
The present composition obtaining by above-described embodiment being provided by Beijing Hao Yuankang Science and Technology Ltd..
1.2 laboratory animal
The healthy clean level female mice of Kunming kind, by Beijing, China biotech inc, Fukang provides, and body weight 26 ± 2g. laboratory animal occupancy permit number is SYXK (capital) 2012-0031.
1.3 dosage group selections and tested material give mode
Three dosage groups and a model control group.The recommended dose of human body is 4.0g/ days, and three dosage group dosage is respectively 5 times, 10 times, 30 times of human body recommended dose.Take respectively tested material, with distilled water, be assigned to 100ml, as the tested material of basic, normal, high three dosage groups, model control group gives equivalent distilled water.Establish two intact animal's groups simultaneously, give respectively high dose tested material and distilled water.
Per os gives tested material, and gavage amount is 20ml/kg.BW.
1.4 key instruments and reagent
Alloxan, purchased from U.S. Sigma company
Medisence Optium blood glucose meter, is produced by U.S. Abbott Laboratories company limited.
Abbott Laboratories' (ANTU) blood sugar test paper, is produced by U.S. Abbott Laboratories company limited.
1.5 test method
1.5.1 reduce fasting glucose experiment
1.5.1.1 intact animal
Select 20 of Healthy female mices, fasting 5 hours, gets tail blood and surveys blood glucose value.According to blood sugar level, be divided at random 2 groups, 10 every group, be respectively high dose group, Normal group.High dose group gives tested material, and normal dose group gives distilled water, and gavage amount: 20ml/kg.BW gives after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively two treated animal blood glucose values.
1.5.1.2 hyperglycemia model animal
Select the Healthy female mice fasting of body weight 24-28g after 24 hours, tail vein gives alloxan 40mg/kg (administered dose 10ml/kg.BW), and after 6 days, fasting is 5 hours, gets tail blood and surveys blood glucose value.Blood glucose value is hyperglycemia model success animal at 10mmol/L～25mmol/L.According to blood sugar level, be divided at random 4 groups, 10 every group, be respectively model control group, low dose group, middle dosage group and high dose group.Dosage group gives the tested material of respective concentration, and model control group gives distilled water, and gavage amount: 20ml/kg.BW gives after 30 days fasting 5 hours continuously, gets tail blood and surveys fasting blood sugar, relatively each treated animal blood glucose value and blood glucose decline percentage rate.
Blood glucose value * 100% before blood glucose decline percentage rate=(the rear blood glucose value of blood glucose value-test before experiment)/experiment
1.5.2 resistance to sugar amount experiment
Laboratory animal reduces fasting glucose experiment (hyperglycemia model animal).Dosage group gives the tested material of respective concentration, model control group gives distilled water, gavage amount: 20ml/kg.BW, give continuously after 30 days fasting 5 hours, dosage group gives the tested material of respective concentration again, model control group gives distilled water, within 20 minutes, by mouth, give glucose 2.0g/kg, get tail hematometry to glucose after the blood glucose value (blood glucose value of 0 hour can be used as fasting blood sugar) of 0,0.5,2 hour, computation model matched group and tested material group to glucose after the variation of each time point Area under the curve of blood glucose, as resistance to sugar amount observation index.
Area under the curve of blood glucose=0.25 * (0 hours blood glucose value+3 * 2, hours blood glucose value+4 * 0.5 hours blood glucose value)
1.5 respectively organize data all adopts SPSS11.5FOR WINDOWS to carry out systematic analysis.Wherein intact animal adopts T-check, and animal pattern adopts variance analysis and check between two, and as heterogeneity of variance, person adopts data transaction, still unevenly after conversion adopts rank test.
2, result
2.1 impacts on laboratory animal body weight: (in Table 1,2)
The impact of table 1 tested material on normal Mouse Weight
The impact of table 2 tested material on hyperglycemia model Mouse Weight
From table 1,2, each dosage treated animal weightening finish is compared with corresponding matched group, and there are no significant for difference (P>0.05)
2.2 impacts on normal mouse fasting glucose
Table 3 tested material is on the impact of normal mouse fasting glucose (mmol/L)
From table 3, per os gave the tested material of high dose after 30 days, and normal mouse fasting glucose is compared with Normal group, no significant difference (P>0.05).
2.3 impacts on hyperglycemia model mice fasting glucose
Table 4 tested material is on hyperglycemia model mice fasting glucose and the percentile impact that declines
From table 4, with the tested material gavage hyperglycemia model mice of various dose after 30 days, basic, normal, high dosage group fasting glucose is all lower than model control group, and low, high dose group blood glucose decline percentage rate is all higher than model control group, and difference all has significance (P<0.05).
2.4 impacts that the resistance to sugar of diabetic mice is measured
The impact of table 5 tested material on the resistance to sugar amount of diabetic mice
From table 5, with the tested material gavage hyperglycemia model mice of various dose, after 30 days, each time point Area under the curve of blood glucose of high dose group is lower than model control group, and difference has significance (P<0.05).
3. brief summary
With the tested material gavage mice of various dose, after 30 days, each dosage treated animal weightening finish is compared with corresponding matched group, and there are no significant for difference (P>0.05); In normal mouse, the fasting glucose of high dose group is compared with Normal group, no significant difference (P>0.05); In model mice, basic, normal, high dosage group fasting glucose is all lower than model control group, and low, high dose group blood glucose decline percentage rate is all higher than model control group, and difference all has significance (P<0.05); In the test of resistance to sugar amount, each time point Area under the curve of blood glucose of high dose group is lower than model control group, and difference has significance (P<0.05).Show that tested material has function of blood sugar reduction.
The curative effect of test example 2 present composition blood fat reducing
1 experiment material
1.1 laboratory animals are selected totally 60 of the SD male and healthy rats of National Institute for Food and Drugs Control [credit number: SCXK-(capital) 2009-0017] breeding, body weight 180 ± 20g.
1.2 medicines and reagent
121441), Triglyceride Reagent box (lot number: 125671), HDL-C test kit (lot number: 120731) be Zhongsheng Beikong Biological Science & Technology Co., Ltd. and produce T-CHOL test kit (lot number:.
1.3 high lipid foods fill a prescription 78.8% normal feedstuff, 1% cholesterol, 10% yolk powder, 10% Adeps Sus domestica, 0.2% cholate.Normal feedstuff is produced by Beijing China biotech inc, Fukang [credit number: SCXK-(capital) 2012-0031].
1.4 instrument SELECTRA-E automatic clinical chemistry analyzers (2005001), centrifuge (98090).
2 experimental techniques
2.1 groupings are divided into five groups at random by laboratory animal: normal feedstuff matched group, hyperlipidemia model group, low dose group, middle dosage group and high dose group, three dosage group dosage is respectively 5 times, 10 times, 30 times of human body recommended dose, and the recommended dose of human body is 4.0g/ days.
2.2 modelings and medication adopt preventative high fat animal model experiment method.The tested material of dosage group gavage various dose when giving high lipid food; The water (sterilizing) of gavage respective volume when high fat matched group gives high lipid food.Rat oral gavage volume is that 0.5mL/100g Mus is heavy.
2.3 methods are fed rat after 8 days with detecting normal feedstuff, spend the night and get tail blood on an empty stomach, survey serum TC, TG, HDL-C level, according to TC level, with reference to above-mentioned grouping, are divided at random 5 groups. and three dosage groups give high lipid food and different agent simultaneously
The tested material of amount; Hyperlipidemia model matched group gives high lipid food and distilled water; Normal feedstuff matched group gives normal feedstuff and distilled water.Administration was weighed after 30 days, after fasting 16h, got blood, surveyed triglyceride (TG), cholesterol (TC), HDL-C (HDL-C).
2.4 date processing carry out date processing with SPSS software, and measurement data data are with mean ± standard deviation) (X ± SD) represent, adopts variance analysis, relatively adopts between two LSD-t check, take P≤0.05 has statistical significance as difference.
3 results
From table 1, the body weight of each dosed administration treated animal is approaching with hyperlipidemia model matched group before treatment, in therapeutic process and after treatment, difference not statistically significant (p ﹥ 0.05), illustrates that tested material has no significant effect the body weight of animal under this experiment condition.
From table 2, feed high lipid food after 30 days, TC in the serum of animal, TG significantly raises, and with the comparison of normal feedstuff group, difference has height statistical significance (P ﹤ 0.01), illustrates that hyperlipidemia model is successfully established.The tested material administration of middle and high dosage group within 30 days, can reduce in rat blood serum TC and with the comparison of hyperlipidemia model matched group, difference has statistical significance (P ﹤ 0.05).The tested material of basic, normal, high three dosage groups all can reduce the TG in rat blood serum, and with the comparison of hyperlipidemia model matched group, difference has height statistics meaning (P ﹤ 0.01).In three dosage group rat blood serums, the level of HDL-C and hyperlipidemia model matched group approach, difference not statistically significant, and these presentation of results tested materials have reducing effect to the TC in rat blood serum, TG, and to HDL-C
There is no obvious effect, prompting, under this experiment condition, tested material raises and has preventive effect the rat fat of high lipid food induction.
the impact of table 1 tested material on the weight of animals
table 2 tested material on animal blood impact
With the comparison of hyperlipidemia model matched group, * P ﹤ 0.05, * * P ﹤ 0.01.
The curative effect of test example 3 present composition therapeutical chemistry liver damages
1, materials and methods
1.1 laboratory animal
SPF level Male Kunming strain mice, weight 18～22g, 100, animal feeding room temperature is 22～24 ℃,
Humidity is 65%～75%.By Beijing, China biotech inc, Fukang provides.Laboratory animal occupancy permit number is SYXK (capital) 2012-0031.
1.2 medicines and preparation
1.2.1 Hao Yuankang Science and Technology Ltd. in tested material Beijing provides, and is chocolate brown powder shape solid.It is 4.0g/60kg BW that human body is recommended daily intaking amount.According to test requirements document, it is standby for test that the tested material adding distil water that takes various dose is mixed with the turbid solution of desired concn.
1.2.2 carbon tetrachloride carbon tetrachloride (CCl4) analytical pure, by Solution on Chemical Reagents in Shanghai, factory produces, lot number 20120519.
1.3 experiment groupings and dosage design
Chemical liver injury experiment is divided into 5 groups at random by laboratory animal, and 20 every group, by crowd's daily intaking amount (4.0g/60kg BW), expand respectively 5,10,30 times as basic, normal, high dosage group, separately establish hepatic injury matched group and solvent control group.
1.4 experimental technique
1.4.1 tested material is mixed with desired concn by 1.2.1 method and puts Refrigerator store, and 1. laboratory animal per os every day gavage is given, and gavage capacity is 0.1ml/10gBW, and solvent control group and positive controls give equivalent solvent control liquid.Animal weighs weekly twice, by changes of body mass, adjusts tested material dosage, and in testing the 30th day by each treated animal fasting 16h overnight, hepatic injury group and each dosage group once give the CCl of 0.5% (V/V) through lumbar injection
4oil solution 0.1ml/10g BW, solvent control group gives the solvent (salad oil 5%, distillation monoglyceride 1.5%, distilled water 93.5%) of equivalent through preparing, when tested material group continues to give tested material to experiment end.Give CCl
4after 24h and 48h, put to death animal (needing fasting 16h before execution) and carry out the detection of indices.
1.4.2 hepatic pathology is observed material
According to tested material, give CCl
4the trend that 24h and 48h serum two-story valley alanine aminotransferase (ALT), amino transaminase (AST) measured value of Aspartic Acid raise, after selecting 24h and 48h, animal livers is completely fixed by paraffin sections with 40g/L formaldehyde immediately, and HE dyeing is also dying micro-Microscopic observation hepatocyte injury degree at optics.
1.5 detect index
The mensuration of serum alt, AST, adopts SABA-18 type Italy to originate from Automatic Biochemical Analyzer, middle life
Bei Kong biotech inc corresponding reagent box is measured.
The all own control data of 1.6 date processing adopt paired t-test, two groups of means adopt t check in groups, and the latter need carry out homogeneity test of variance, and the data of nonnormal distribution or heterogeneity of variance are carried out to suitable variable conversion, wait meet normal state variance neat after, by the data of changing, carry out t check.
2 experimental results
Experiment mice serum alt, AST result give CCl
4rear hepatic injury control group A LT and AST value obviously raise, each dosage treated animal serum alt and AST value and the comparison of hepatic injury group, and difference has significance (P<0.01).In Table 1.
table 1 is respectively organized mice serum ALT, AST measured value
Note: with positive controls comparison, * P<0.05.
Hepatocellular damage is the main manifestations of chemical liver injury.Can be caused by toxicity mesostate, another approach is the free radical being produced by P450 oxidation reaction, with protein or the non-saturated fatty acid covalent bond on cell membrane, produces lipid peroxide and causes cell membrane damage.This experimental studies results confirms: give each dosage treated animal serum alt and AST value and the comparison of hepatic injury group after CCl4, difference has significance (P<0.01).By observed result under hepatic pathology histology light microscopic, show each dosage group of tested material and the comparison of hepatic injury matched group, hepatocellular degeneration, downright bad slight, impaired hepatocyte is dark karyokinesis phase and hepatocyte and newborn blood capillary and the bile duct of visible stain around, these are changed to a kind of sign of liver cell regeneration, especially obvious with liver after 48h.Illustrate that the present composition can protect hepatocyte, promote the effect of liver cell regeneration.
Above-described embodiment is described the preferred embodiment of the present invention; not scope of the present invention is limited; design under the prerequisite of spirit not departing from the present invention; various distortion and improvement that those of ordinary skills make technical scheme of the present invention, all should fall in the definite protection domain of the claims in the present invention book.
Claims (8)
1. a blood sugar lowering, blood fat reducing, the compositions of liver protection effect, it is characterized in that, the component that comprises following weight portion: Fructus Momordicae charantiae extract 480-720 part, Cortex Cinnamomi extract 400-600 part, Radix Puerariae 400-600 part, Semen Cassiae 480-720 part, Fructus Lycii 480-720 part, Pericarpium Vitis viniferae extract 240-360 part, Radix Ginseng extract 320-480 part, Rich chromium yeast 20-30 part, phylloxanthin 12-18 part, magnesium oxide 320-480 part, zinc oxide 16-24 part, VB11 2.8-19.2 part, vitamin B2 12.8-19.2 part, vitamin B6 6.4-9.6 part, folic acid 0.28-0.42 part, vitamin B12 0.0064-0.0096 part.
2. compositions according to claim 1, it is characterized in that, comprise the component of following weight portion: 600 parts of Fructus Momordicae charantiae extracts, 500 parts of Cortex Cinnamomi extracts, 500 parts of Radix Puerariaes, 600 parts of Semen Cassiaes, 600 parts of Fructus Lycii, 300 parts of Pericarpium Vitis viniferae extract, 400 parts of Radix Ginseng extracts, 25 parts of Rich chromium yeasts, 15 parts of phylloxanthins, 400 parts of magnesium oxide, 20 parts of zinc oxide, 6 parts of VB11s, 16 parts of vitamin Bies, 8 parts of vitamin Bies, 0.35 part, folic acid, 0.008 part of vitamin B12.
3. compositions according to claim 1, is characterized in that: it is the various conventional oral preparation of Chinese traditional medicinal that contains or do not contain pharmaceutic adjuvant.
4. compositions according to claim 3, is characterized in that: described preparation is powder, capsule, tablet or granule.
5. the method for preparing powder described in claim 4, capsule, tablet, is characterized in that: take the raw material of weight proportion described in claim 1, pack and obtain powder after mix homogeneously; Fill capsule after raw material mix homogeneously is obtained to capsule, or after raw material mix homogeneously, add silicon dioxide or magnesium stearate fill capsule to obtain capsule; By raw material mix homogeneously described in claim 1, add microcrystalline Cellulose, carboxymethyl starch sodium, and use PVP K30 pelletize, then add lubricant, tabletting obtains tablet or granulator granulation obtains granule.
6. method according to claim 4, is characterized in that: the addition of silicon dioxide or magnesium stearate accounts for the 0.8-1.2% of gross weight.
7. method according to claim 4, is characterized in that: the weight ratio of described microcrystalline Cellulose and compositions is 1:4, and the weight ratio of described carboxymethyl starch sodium and compositions is 1:20, and the weight ratio of described PVP K30 and compositions is 1:33.
8. the application of the compositions described in claim 1-4 any one, is characterized in that: use it for health food or medicine that preparation has blood sugar lowering, blood fat reducing, liver protection effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410193441.8A CN103989835A (en) | 2014-05-08 | 2014-05-08 | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410193441.8A CN103989835A (en) | 2014-05-08 | 2014-05-08 | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103989835A true CN103989835A (en) | 2014-08-20 |
Family
ID=51304335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410193441.8A Pending CN103989835A (en) | 2014-05-08 | 2014-05-08 | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989835A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940295A (en) * | 2015-06-24 | 2015-09-30 | 天津天狮生物发展有限公司 | Blood fat reducing composition |
| CN106361908A (en) * | 2016-10-28 | 2017-02-01 | 青岛东海药业有限公司 | Composition and application thereof |
| CN109820017A (en) * | 2017-11-23 | 2019-05-31 | 天津市什祥斋食品有限公司 | A kind of fried dough twist of lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110697A (en) * | 2013-02-01 | 2013-05-22 | 北京润康普瑞生物技术有限公司 | Pharmaceutical composition with hypoglycemic effect |
-
2014
- 2014-05-08 CN CN201410193441.8A patent/CN103989835A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103110697A (en) * | 2013-02-01 | 2013-05-22 | 北京润康普瑞生物技术有限公司 | Pharmaceutical composition with hypoglycemic effect |
Non-Patent Citations (3)
| Title |
|---|
| 李淑敬等: "枸杞子对糖尿病的辅助治疗作用", 《中国保健营养》 * |
| 王虎: "天然降糖有效成分及药理作用的研究进展", 《中国医院药学杂志》 * |
| 邹礼根等: "天然色素的种类", 《农产品加工副产物综合利用技术》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940295A (en) * | 2015-06-24 | 2015-09-30 | 天津天狮生物发展有限公司 | Blood fat reducing composition |
| CN106361908A (en) * | 2016-10-28 | 2017-02-01 | 青岛东海药业有限公司 | Composition and application thereof |
| CN109820017A (en) * | 2017-11-23 | 2019-05-31 | 天津市什祥斋食品有限公司 | A kind of fried dough twist of lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100400075C (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
| CN101019645B (en) | Health food for remitting fatigue and raising hypoxia tolerance and its preparation method | |
| CN103989835A (en) | Composition for reducing blood sugar, decreasing blood fat and protecting liver and preparation method and application thereof | |
| CN101999663A (en) | Application of traditional Chinese medicine combination in preparing healthcare food and medicine capable of releasing physical fatigue | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN102511821B (en) | Composite lipid-lowering soft capsule preparation prepared by lycopene and grapestone extracts and preparation method of composite lipid-lowering soft capsule preparation | |
| CN101356975A (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN102366497B (en) | Medicinal compound preparation for treating diabetes and preparation method of medicinal compound preparation | |
| CN105941562A (en) | Health-care biscuit for preventing and treating hyperglycemia | |
| CN103816278A (en) | Composition for reducing blood sugar and application thereof | |
| CN102526264B (en) | Chinese medicinal preparation with blood fat reducing effect and preparation method thereof | |
| CN104127816B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN108310226A (en) | It is a kind of to have effects that prevent the composition and the preparation method and application thereof of diabetes | |
| CN100493573C (en) | Chinese traditional medicine composition for lowering blood sugar and its preparation | |
| CN101879190A (en) | Composition containing curcumin and application of curcumin in preparing composition for adjusting blood sugar | |
| CN106562415A (en) | Health food and preparation method thereof | |
| CN102266428A (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN106880784A (en) | It is a kind of with fatigue-relieving, the Chinese medicine composition of anti-aging and its application | |
| CN102885300A (en) | Health-care food with blood sugar reducing effect and preparation method thereof | |
| CN1311853C (en) | Quick release Yuquan micropill | |
| CN1311852C (en) | Yuquan extractum and its medicine composition and use | |
| CN109157584A (en) | A kind of composition and its preparation method and application with auxiliary lipid-lowering function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140820 |